Thin Film Drugs Market Size and Share
Market Overview
| Study Period | 2019 - 2030 |
|---|---|
| Market Size (2025) | USD 11.71 Billion |
| Market Size (2030) | USD 18.29 Billion |
| Growth Rate (2025 - 2030) | 9.32% CAGR |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. |
|
Thin Film Drugs Market Analysis by Mordor Intelligence
The thin film drug market size reached USD 11.71 billion in 2025 and is forecast to touch USD 18.29 billion by 2030, advancing at a 9.32% CAGR. Demand growth stems from an aging global population, mounting dysphagia prevalence, and regulatory encouragement for patient-centric formulations. Manufacturers are capitalizing on superior adherence profiles, rapid onset of action, and the ability to tailor dose strengths for vulnerable groups. Investments in hot-melt extrusion and solvent-casting lines are lowering production costs, while microneedle innovations position the technology to address chronic disease management needs in outpatient settings. Competitive strategies emphasize partnerships between formulation specialists and large pharmaceutical companies to shorten development timelines and widen therapeutic scope.
Key Report Takeaways
- By product category, oral thin films led with 70.51% of thin film drug market share in 2024; transdermal thin films are projected to expand at a 13.65% CAGR through 2030.
- By therapeutic indication, opioid use disorder captured 36.53% of the thin film drug market size in 2024, while chronic pain is forecast to grow at 11.85% CAGR between 2025 and 2030.
- By distribution channel, hospital pharmacies accounted for 46.21% of the thin film drug market size in 2024; online pharmacies post the highest projected CAGR at 15.87% to 2030.
- By drug type, prescription formats held 72.12% of the thin film drug market size in 2024, whereas over-the-counter variants are advancing at 12.71% CAGR.
- By geography, North America contributed 41.32% of 2024 revenue, whereas Asia-Pacific is on track for a 10.61% CAGR to 2030.
Global Thin Film Drugs Market Trends and Insights
Drivers Impact Analysis
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising prevalence of dysphagia & geriatric population | +2.1% | Global; strongest in North America and Europe | Long term (≥ 4 years) |
| Increasing approvals & investments in thin-film therapeutics | +1.8% | North America and Europe; Asia-Pacific emerging | Medium term (2-4 years) |
| Superior patient compliance versus conventional dosage forms | +1.4% | Global | Medium term (2-4 years) |
| Opioid-harm-reduction policies accelerating buccal film uptake | +0.9% | North America primary; Europe secondary | Short term (≤ 2 years) |
| Hot-melt-extrusion HPMC grades enable higher-dose, heat-sensitive APIs | +0.7% | Global manufacturing hubs | Long term (≥ 4 years) |
| Source: Mordor Intelligence | |||
Rising Prevalence Of Dysphagia & Geriatric Population
Dysphagia affects 36.9% of nursing-home residents and 27% of older adults, creating a large cohort unable to swallow conventional tablets[1]Norio Watanabe et al., “Survey of Dysphagia and Related Medications in Nursing Home Residents,” Journal of Pharmaceutical Health Care and Sciences, JPHCS.BIOMEDCENTRAL.COM. Beyond age-related issues, neurological disorders and post-surgical complications amplify demand for alternate dosage forms. Health systems incur significant costs from aspiration pneumonia and non-adherence, prompting reimbursement support for film formulations. Pediatric use cases reinforce universal applicability, while community pharmacists using EAT-10 screening tools now flag swallowing issues earlier, broadening product access points.
Increasing Approvals & Investments In Thin-Film Therapeutics
RizaFilm’s 2024 FDA clearance for migraine relief underlined the agency’s confidence in thin film platforms. Aquestive’s NDA for Anaphylm demonstrates how sublingual epinephrine could disrupt autoinjectors through needle-free delivery[2]“Aquestive Completes NDA Submission for Anaphylm,” Aquestive Therapeutics, AQUESTIVE.COM. Large companies channel new spending into U.S. manufacturing: Johnson & Johnson alone announced USD 55 billion for advanced dosage capabilities, signaling sustained capital flow toward film technologies. Clearer bioequivalence guidelines now reduce regulatory uncertainty, encouraging venture capital to back specialized developers.
Superior Patient Compliance Versus Conventional Dosage Forms
Clinical data show orodispersible formulations lower hospitalization odds by 64.5% and relapse by 63.2% in non-adherent psychiatric patients. Thin films dissolve quickly, avoid water, and allow taste masking, boosting acceptance among children and the elderly. Payers reward therapies that cut readmissions, enabling premium pricing. Manufacturers highlight compliance benefits to differentiate from generic tablets, particularly where adherence drives therapeutic outcomes.
Opioid-Harm-Reduction Policies Accelerating Buccal Film Uptake
Federal initiatives prioritizing medication-assisted treatment have expanded buprenorphine coverage, and buccal films reduce diversion risk compared with tablets. Evidence that extended-release buprenorphine aids fentanyl-using populations further validates film approaches. Public-health alignment assures steady procurement, anchoring revenue visibility for producers through 2030.
Restraints Impact Analysis
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Availability of substitute dosage forms (ODTs, injectables) | -1.6% | Global | Medium term (2-4 years) |
| Moisture-sensitivity driving high-cost barrier packaging | -1.2% | Global manufacturing hubs | Long term (≥ 4 years) |
| Limited solvent-casting capacity for high-potency APIs | -0.8% | North America & Europe manufacturing centers | Medium term (2-4 years) |
| Source: Mordor Intelligence | |||
Availability Of Substitute Dosage Forms (ODTs, Injectables)
Orally disintegrating tablets enjoy mature production lines and lower costs, curbing thin film uptake in price-sensitive categories. European Pharmacopoeia recognition of ODTs ensures streamlined approvals, while injectables remain dominant where precise pharmacokinetics matter, such as oncology. Established infrastructure and falling generic prices limit thin film pricing power when convenience alone is the differentiator.
Moisture-Sensitivity Driving High-Cost Barrier Packaging
Thin films are hygroscopic, so firms often allocate 15-20% of product cost to barrier packs. Research warns that some coatings can accelerate degradation, pushing developers toward custom multilayer formats. Reliance on single suppliers for specialty foils adds supply risk, and complex packaging undermines sustainability targets, pressuring manufacturers to invest in formulation tweaks that tolerate higher humidity.
Segment Analysis
By Product Type: Oral Films Dominate Despite Transdermal Acceleration
Oral films captured 70.51% of thin film drug market share in 2024 thanks to straightforward regulatory paths and cost-effective solvent-casting lines. Transdermal formats post a 13.65% CAGR to 2030 as microneedle-integrated patches broaden drug classes deliverable through skin.
Manufacturers can scale oral films rapidly, leveraging hot-melt extrusion to incorporate poorly soluble APIs. Transdermal films require precise micro-fabrication and adhesive engineering, limiting large-scale output today. Nonetheless, vaccine delivery and hormone therapy trials are yielding positive acceptance data, indicating transdermal systems will narrow the gap during the forecast horizon[3]Hye Jin Choi et al., “Microneedle Patch Casting Using a Micromachined Carbon Master,” Scientific Reports, NATURE.COM.
By Indication: Opioid Crisis Drives Market Leadership
Opioid use disorder dominated with 36.53% of thin film drug market size in 2024 because buprenorphine films align with government harm-reduction goals. Chronic pain films exhibit the fastest 11.85% CAGR as prescribers pivot to non-opioid molecules that benefit from rapid oromucosal absorption.
Migraine therapies gain traction after RizaFilm’s clearance, enabling in-home treatment during nausea episodes. Sublingual immunotherapy films in allergy care and emergency systemic delivery for anaphylaxis show promise, diversifying the clinical portfolio. Collectively, these indications reinforce a broad therapeutic runway for the thin film drug market.
By Distribution Channel: Online Growth Disrupts Traditional Patterns
Hospital pharmacies retained 46.21% of thin film drug market size in 2024 because controlled substances and specialty drugs require clinical oversight. Online pharmacies post 15.87% CAGR, fueled by telehealth adoption and relaxed shipping regulations for temperature-stable films.
Retail chains bridge routine prescriptions, but digital platforms now integrate medication adherence tools, offering refill reminders tailored to film regimens. For immobile patients or rural communities, mail-order fulfillment circumvents access barriers, further expanding the thin film drug market.
Note: Segment shares of all individual segments available upon report purchase
By Drug Type: Prescription Dominance Reflects Complexity
Prescription films commanded 72.12% share in 2024, reflecting stringent dosing requirements and reimbursement frameworks that support higher prices. Over-the-counter products rise at 12.71% CAGR as taste-masked vitamins and antihistamines transition to consumer aisles.
Improved manufacturing yields reduce cost per dose, making OTC conversion economically viable. However, regulatory agencies insist on extensive consumer-use evidence, so large firms with deep clinical datasets hold an advantage in switching pathways.
Geography Analysis
North America led with 41.32% share in 2024, supported by FDA guidance that clarifies bioequivalence and stability expectations. Robust insurance coverage and specialty pharmacy networks expedite market entry, while sizable investments in continuous manufacturing ensure domestic capacity for rapid scale-up.
Europe maintains second position through centralized approvals that streamline multi-country launches. Emphasis on patient safety and high adherence among seniors underpins demand. Regional CDMOs specialize in solvent-casting and HME, serving global supply chains.
Asia-Pacific posts 10.61% CAGR to 2030, propelled by regulatory harmonization and expanded manufacturing grants in China, India, and South Korea. Lower labor costs and government incentives attract technology-transfer deals, positioning the region as a production hub for global thin film drug market exports. Rising healthcare spending and urbanization open large patient pools receptive to convenient dosage forms.
Competitive Landscape
The thin film drug market is moderately fragmented. Pioneers such as Aquestive Therapeutics and Indivior leverage proprietary solvents, laminate structures, and taste-masking chemistries to guard intellectual property. Exclusive supply contracts with large pharma partners ensure stable order books.
Emerging players focus on microneedle patches and polymer science to broaden application areas beyond oral mucosa. Partnerships dominate strategy: innovator firms license film technologies to companies seeking lifecycle management for expiring brands. Large multinationals increasingly acquire specialty formulators to secure manufacturing know-how and de-risk development.
Competition centers on dose-loading efficiency, dissolution time, and packaging advancements. Companies able to integrate continuous HME with real-time analytics gain a cost edge. Others court differentiation through flavor profiles and child-resistant yet senior-friendly single-dose pouches.
Thin Film Drugs Industry Leaders
-
Aquestive Therapeutics
-
Indivior PLC
-
Pfizer, Inc.
-
ZIM Laboratories
-
Tesa SE (Tesa Labtec)
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- June 2025: BioNxt Solutions Inc. launched a feasibility study to create an oral dissolvable film of semaglutide targeting diabetes and obesity patients.
- June 2025: IntelGenx rebranded to Nualtis, aligning corporate identity with its long-term oral film strategy.
Global Thin Film Drugs Market Report Scope
As per the report's scope, thin film drugs have surfaced as an alternative to tablets or capsules due to their efficient therapeutic results. The drugs are made of polymers that quickly dissolve when kept in the mouth or buccal cavity, supplying the drug directly to the systemic circulation in the body. The Thin Film Drugs Market is segmented by Product Type (Oral Thin Film, Transdermal Thin Film), By Indication (Schizophrenia, Migraine, Opioid Dependence, and Others), and by geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The by eport also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| Oral Thin Films | Orodispersible Films |
| Sublingual Films | |
| Buccal Films | |
| Transdermal Thin Films | Passive Patches |
| Active / Microneedle-assisted Patches |
| Schizophrenia |
| Migraine |
| Opioid Use Disorder |
| Nausea & Vomiting |
| Chronic Pain |
| Allergy & Asthma |
| Hospital Pharmacies |
| Retail Pharmacies |
| Online Pharmacies |
| Prescription (Rx) |
| Over-the-Counter (OTC) |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| South Korea | |
| Australia | |
| Rest of Asia-Pacific | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
| By Product Type | Oral Thin Films | Orodispersible Films |
| Sublingual Films | ||
| Buccal Films | ||
| Transdermal Thin Films | Passive Patches | |
| Active / Microneedle-assisted Patches | ||
| By Indication | Schizophrenia | |
| Migraine | ||
| Opioid Use Disorder | ||
| Nausea & Vomiting | ||
| Chronic Pain | ||
| Allergy & Asthma | ||
| By Distribution Channel | Hospital Pharmacies | |
| Retail Pharmacies | ||
| Online Pharmacies | ||
| By Drug Type | Prescription (Rx) | |
| Over-the-Counter (OTC) | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Europe | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Asia-Pacific | China | |
| Japan | ||
| India | ||
| South Korea | ||
| Australia | ||
| Rest of Asia-Pacific | ||
| Middle East and Africa | GCC | |
| South Africa | ||
| Rest of Middle East and Africa | ||
| South America | Brazil | |
| Argentina | ||
| Rest of South America | ||
Key Questions Answered in the Report
What is the current value of the thin film drug market?
The thin film drug market size stood at USD 11.71 billion in 2025 and is projected to rise to USD 18.29 billion by 2030.
Which product type dominates the thin film drug market?
Oral thin films lead with 70.51% market share in 2024, thanks to mature manufacturing and clear regulatory pathways.
Why are online pharmacies growing so quickly for thin film products?
Relaxed shipping regulations and telehealth integration support a 15.87% CAGR for online channels, giving patients convenient access to specialty films.
How do thin films help address the opioid crisis?
Buccal buprenorphine films align with harm-reduction policies, offer diversion resistance, and hold 36.53% share within therapeutic indications.
What is the biggest technical restraint facing thin film manufacturers?
Moisture-sensitivity demands expensive barrier packaging, which can add up to 20% to total product cost and complicate sustainability goals.
Page last updated on:
